Search This Blog

Sunday, September 19, 2021

SARS-CoV-2 evolving to get better at becoming airborne

 Results of a new study led by the University of Maryland School of Public Health show that people infected with the virus that causes COVID-19 exhale infectious virus in their breath—and those infected with the Alpha variant (the dominant strain circulating at the time this study was conducted) put 43 to 100 times more virus into the air than people infected with the original strains of the virus. The researchers also found that loose-fitting cloth and surgical masks reduced the amount of virus that gets into the air around infected people by about half. The study was published in Clinical Infectious Diseases.

"Our latest study provides further evidence of the importance of airborne transmission," said Dr. Don Milton, professor of environmental health at the University of Maryland School of Public Health (UMD SPH). "We know that the Delta variant circulating now is even more contagious than the Alpha variant. Our research indicates that the variants just keep getting better at traveling through the air, so we must provide better ventilation and wear tight-fitting masks, in addition to vaccination, to help stop spread of the ."

The amount of virus in the air coming from Alpha variant infections was much more—18-times more—than could be explained by the increased amounts of virus in nasal swabs and saliva. One of the lead authors, doctoral student Jianyu Lai, explained, "We already knew that virus in saliva and nasal swabs was increased in Alpha variant infections. Virus from the nose and mouth might be transmitted by sprays of large droplets up close to an infected person. But, our study shows that the virus in exhaled aerosols is increasing even more." These major increases in airborne virus from Alpha infections occurred before the Delta  arrived and indicate that the virus is evolving to be better at traveling through the air.

To test whether  work in blocking the virus from being transmitted among people, this study measured how much SARS-CoV-2 is breathed into the air and tested how much less virus people sick with COVID-19 exhaled into the air after putting on a cloth or surgical mask. Face coverings significantly reduced virus-laden particles in the air around the person with COVID-19, cutting the amount by about 50%. Unfortunately, the loose-fitting cloth and  didn't stop infectious virus from getting into the air.

Dr. Jennifer German, a co-author, said, "The take-home messages from this paper are that the coronavirus can be in your exhaled breath, is getting better at being in your exhaled breath, and using a mask reduces the chance of you breathing it on others." This means that a layered approach to control measures (including improved ventilation, increased filtration, UV air sanitation, and tight-fitting , in addition to vaccination) is critical to protect people in public-facing jobs and indoor spaces.

More information: Oluwasanmi O Adenaiye et al, Infectious SARS-CoV-2 in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection, Clinical Infectious Diseases (2021). DOI: 10.1093/cid/ciab797

https://medicalxpress.com/news/2021-09-covid-evolving-airborne.html

Way bats resist covid could inform new treatments in humans

 A paper published in the prestigious journal, Science Immunology, explores the idea that studying bats' responses to SARS-CoV-2 may provide key insights into how and when to best use existing therapies for COVID-19, and to develop new treatments.

The review, led by Professor Marcel Nold and Associate Professor Claudia Nold, from Monash University's Department of Paediatrics and Hudson Institute of Medical Research, written in collaboration with colleagues in Australia and China, is a major review of how the virus that has caused the current pandemic wreaks havoc on the .

Since first identified in December 2019, SARS-CoV-2 has mutated, and the variant strains Alpha, Beta and Delta are more infectious than the original strain. Specifically, the Delta strain is 60-79 per cent more transmissible again than the Alpha mutant, and presumably more deadly, according to Professor Nold.

He says there remains an urgent "need for effective therapies, at least in part because of the emergence of mutations."

The authors warn that "preventing SARS-CoV-2 infection, or enabling patients to eradicate it, represents the ultimate goal in combating COVID-19: but it is uncertain when either will become reliably possible."

"Therefore, efforts at identifying safe and effective therapies to prevent COVID from progressing to the moderate and severe disease stages, are critical in the fight against the disease," Professor Nold said.

Bats contract the virus but show minimal disease. The authors say that "preventing progression to severe disease, or effectively treating it—in other words emulating —would markedly relieve suffering and save lives."

According to Associate Professor Nold, studying the way bats resist coronaviruses holds substantial promise not only for infections with SARS-CoV-2, but will also "better prepare us for the next epidemic or pandemic."

The review says the common ancestor to the current COVID virus likely appeared in bats between 40 and 70 years ago, "though the exact bat species or intermediate host involved in the 2019 outbreak remains elusive."

While bats can infect each other with SARS-CoV-2 they show no clinical effects nor show the same issues in the lungs that impact humans so badly.

The authors suggest that some of the ways bats appear to resist COVID could be used in therapeutics such as fine-tuning the human immune response to the virus in ways that bats seem to use, including boosting type I and III interferon responses or—once severe illness has developed—blocking inflammasomes to mimic what happens in bats.

Associate Professor Nold says this "could minimise the excessive inflammation, immune exhaustion and the cytokine storms that are experienced in humans."

Based on these insights, the cross disciplinary authors comment on the best strategies regarding choice and timing of various treatments available today, and on currently underdeveloped avenues that may hold promise in relieving the suffering caused by COVID-19 worldwide.

More information: Of Bats and Men: Immunomodulartory Treatment Options for COVID-19 Guided by the Immunopathology of SARS-CoV-2 Infection, Science Immunology (2021). DOI: 10.1126/sciimmunol.abd0205

https://medicalxpress.com/news/2021-09-lessons-resist-covid-treatments-humans.html

Tumor biotech Pyxis Oncology files for a $100 million IPO

 Pyxis Oncology, a preclinical biotech developing antibody therapies for solid and hematologic tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.


Pyxis is focused on developing next-generation therapies to target difficult-to-treat cancers, with a broad portfolio of novel antibody drug conjugate (ADC) candidates and monoclonal antibody (mAb) preclinical discovery programs. It is developing its ADC candidates and mAb preclinical discovery programs for difficult-to-treat solid and hematologic tumors. Pyxis anticipates submitting INDs for two of its ADC candidates by mid-2022, and another candidate by 2023.

The Cambridge, MA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol PYXO. Pyxis Oncology filed confidentially on June 21, 2021. BofA Securities, Jefferies, Credit Suisse, and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.

Abbott in $119.5M contract for antigen tests

 Abbott Corp., Orlando, Florida, has been awarded a maximum $119,506,023 indefinite-delivery/indefinite-quantity contract for over-the-counter antigen test kits. This was a competitive acquisition with three responses received. This is a one-year contract with no option periods. Location of performance is all 50 states, with a Sept. 14, 2022, ordering period end date. Primary customer is the Department of Health and Human Services. Type of appropriation is fiscal 2021 through 2022 defense working capital funds. The contracting activity is the Defense Logistics Agency Troop Support, Philadelphia, Pennsylvania (SPE2DE-21-D-0048). (Awarded Sept. 14, 2021. 

https://www.defense.gov/Newsroom/Contracts/Contract/Article/2780513/

Quidel gets $710.6M antigen test contract

 Quidel Corp., San Diego, California, has been awarded a maximum $710,570,885 indefinite-delivery/indefinite-quantity contract for over-the-counter antigen test kits. This was a competitive acquisition with three responses received. This is a one-year contract with no option periods. Location of performance is all 50 states, with a Sept. 14, 2022, ordering period end date. Primary customer is the Department of Health and Human Services. Type of appropriation is fiscal 2021 through 2022 defense working capital funds. The contracting activity is the Defense Logistics Agency Troop Support, Philadelphia, Pennsylvania (SPE2DE-21-D-0050). (Awarded Sept. 14, 2021)

https://www.defense.gov/Newsroom/Contracts/Contract/Article/2780513/

Orasure awarded $512.9M contract for antigen test kits

 Orasure Corp., Bethlehem, Pennsylvania, has been awarded a maximum $512,940,000 indefinite-delivery/indefinite-quantity contract for over-the-counter antigen test kits. This was a competitive acquisition with three responses received. This is a one-year contract with no option periods. Location of performance is all 50 states, with a Sept. 14, 2022, ordering period end date. Primary customer is the Department of Health and Human Services. Type of appropriation is fiscal 2021 through 2022 defense working capital funds. The contracting activity is the Defense Logistics Agency Troop Support, Philadelphia, Pennsylvania (SPE2DE-21-D-0049). (Awarded Sept. 14, 2021)

https://www.defense.gov/Newsroom/Contracts/Contract/Article/2780513/

Thermo Fisher issues above-views 2022 guidance

 Thermo Fisher Scientific Inc 

 (Get Free Alerts for TMO) traded higher Friday after the company issued full-year 2022 financial guidance above analyst estimates.

Thermo Fisher expects full-year 2022 earnings of $21.16 per share versus the estimate of $19.68 per share. The company expects full-year 2022 revenue to be $40.3 billion versus the estimate of $34.29 billion. 

https://www.benzinga.com/news/21/09/22994441/why-thermo-fisher-shares-are-trading-higher-today